GLP-1 receptor (GLP-1R) signaling is a promising target of obesity and type 2 diabetes treatment, which aims to activate intestinal GLP-1- and GLP-1R-expressing central nervous system circuits resulting from normal eating and GLP-1R agonist drug therapy [14]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.